Document:

EX-10.5

 Exhibit 10.5 

THE COMPANY HAS APPLIED FOR CONFIDENTIAL TREATMENT OF CERTAIN PROVISIONS OF THIS EXHIBIT WITH THE SECURITIES AND EXCHANGE COMMISSION. THE
CONFIDENTIAL PORTIONS OF THIS EXHIBIT ARE BRACKETED AND MARKED WITH ASTERISKS ([***]) AND HAVE BEEN OMITTED. THE OMITTED PORTIONS OF THIS EXHIBIT WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT. 
 ANTARES PHARMA, INC. 

2008 EQUITY COMPENSATION PLAN 

PERFORMANCE STOCK UNIT SUMMARY OF GRANT 

Antares Pharma, Inc., a Delaware corporation (the “Company”), pursuant to its 2008 Equity Compensation Plan, as amended and
restated (the “Plan”), hereby grants to the individual listed below (the “Grantee”), this performance stock unit award representing the target number of performance stock units set forth below (the “Performance Stock
Units”) that may become earned and vested by the Grantee based on the level of achievement of the Performance Goals. The actual number of Performance Stock Units earned and vested will be based on the actual performance level achieved with
respect to the Performance Goals set forth on Schedule A. The Performance Stock Units are subject in all respects to the terms and conditions set forth herein, in the Performance Stock Unit Award Agreement attached hereto as Exhibit A
(the “Performance Stock Unit Award Agreement”) and the Plan, each of which is incorporated herein by reference and made part hereof. Unless otherwise defined herein, capitalized terms used in this Performance Stock Unit Summary of Grant
(the “Summary of Grant”) and the Performance Stock Unit Award Agreement shall have the meanings set forth in the Plan. 
  

			
	Grantee:	  	[                    ]
		
	Date of Grant:	  	May 29, 2014
		
	Target Award:	  	[                    ] Performance Stock Units
		
	Performance Period:	  	As set forth on Schedule A, either the three or four-year period beginning on January 1, 2014 and ending on December 31, 2016 or December 31, 2017, respectively (each, a “Performance Period”).
		
	Performance Goals:	  	The Performance Goals are based on the three performance measures set forth on Schedule A.
		
	Vesting Schedule:	  	 The Performance Stock Units will become earned and vested based on the performance level achieved with respect to the Performance Goals
and the Grantee’s continued employment or service with the Employer through the last day of the applicable Performance Period (each such day, a “Vesting Date”).
  

The number of Performance Stock Units set forth above is equal to the target number of shares of Company Stock that the Grantee will earn and become vested in
for 100% achievement of the Performance Goals (referred to as the “Target Award”). The actual number of shares of Company Stock that the Grantee will become earned and vested in with respect to the Performance Stock Units may be greater or
less than the Target Award, or even zero, and will be based on the performance level achieved by the Company with respect to the Performance Goals, as set forth on Schedule A. Performance level is measured based on the threshold, target and
maximum performance levels set forth on Schedule A.

			
		  	 Each performance level is calculated as a percentage of target level performance. Threshold performance level is 50% of target, target
performance level is 100% of target and maximum performance level is 150% of target. If actual performance with respect to the net revenue and relative total shareholder return Performance Goals only is between performance levels, the number of
Performance Stock Units earned and vested with respect to those Performance Goals, if any, will be interpolated on a straight line basis for pro-rata achievement of the Performance Goals. Failure to achieve the threshold performance level with
respect to any Performance Goal will result in no Performance Stock Units being earned and vested with respect to that Performance Goal. Any fractional Performance Stock Units resulting from the vesting of the Performance Stock Units in accordance
with the terms herein shall be rounded down to the nearest whole number.
  
 In the event
a Change of Control occurs while the Grantee is employed by, or providing service to, the Employer, the Performance Stock Units will vest as if target performance had been achieved as to each Performance Goal, such that the Target Award is deemed
fully earned and vested as of the date of the Change of Control.

		
	Issuance Schedule:	  	The Grantee will receive a distribution with respect to the Performance Stock Units earned and vested pursuant to this Performance Stock Unit Award, if any, within 60 days following the applicable Vesting Date (each, a
“Payment Date”); provided, however, that such distribution will be made not later than March 15 of the fiscal year following the applicable Vesting Date. Distribution will be made with respect to the Performance Stock Units on the Payment
Date in shares of Company Stock, with each Performance Stock Unit earned and vested equivalent to one share of Company Stock. In no event shall any fractional shares be issued. The Grantee must be employed by, or providing service, to the Employer
on the applicable Vesting Date in order to earn and vest in the Performance Stock Units, unless the Committee determines otherwise.

 Grantee Acceptance: 

By signing the acknowledgement below, the Grantee agrees to be bound by the terms and conditions of the Plan, the Performance Stock Unit Award
Agreement and this Summary of Grant and accepts the Performance Stock Units following the date of the Company’s notification to the Grantee of the award of the Performance Stock Units (the “Notification Date”). The Grantee will accept
as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan, this Summary of Grant or the Performance Stock Unit Award Agreement. 

The Grantee acknowledges delivery of a copy of the Plan and the Plan prospectus together this with this Summary of Grant and the Performance
Stock Unit Award Agreement. Additional copies of the Plan and the Plan prospectus are available upon request by contacting the Chief Financial Officer at (609) 359-3020. 

 

	
	 Agreed and accepted:

	
	  

Grantee

	
	  

Date

  
 2 

 SCHEDULE A 

PERFORMANCE GOALS 

The number of Performance Stock Units that may become earned and vested shall be determined based on the actual performance level achieved
with respect to the following performance measures during the applicable Performance Period: (1) FYE 2016 Net Revenue (“FYE 2016 Net Revenue”); (2) Launch of QST; and (3) FYE 2016 Relative Total Shareholder Return Growth
(“FYE 2016 Relative TSR”) (collectively referred to as the “Performance Goals,” and each individual measure, a “Performance Goal”). The chart below sets forth the applicable weighting and Performance Goals at each
performance level for each performance measure for the applicable Performance Period: 
 For purposes of the (1) FYE 2016 Net Revenue Performance
Goal, the Performance Period is January 1, 2014 – December 31, 2016, (2) Launch of QST, the Performance Period is January 1, 2014 – December 31, 2017 and (3) FYE 2016 Relative TSR, the Performance Period is
January 1, 2014 – December 31, 2016.*  
  

													
	 No.
	  	 Performance

Measure
	  	 Weight
	  	 Performance
Level
	  	 Performance Goals
	  	Performance Stock
Units Earned and
Vested as a
Percentage of Target	 
	 (1)
	  	FYE 2016 Net Revenue**	  	33-1/3%	  	Threshold	  	FYE 2016 Net Revenue of at least $[***] million but less than $[***] million	  	 	50	% 
	  	  	  	Target	  	FYE 2016 Net Revenue of at least $[***] million but less than $[***] million	  	 	100	% 
	  	  	  	Maximum	  	FYE 2016 Net Revenue of $[***] million or above	  	 	150	% 
	 (2)
	  	Launch of QST	  	33-1/3%	  	Threshold	  	Launch of QST by [***]	  	 	50	% 
	  	  	  	Target	  	Launch of QST by [***]	  	 	100	% 
	  	  	  	Maximum	  	Launch of QST by [***]	  	 	150	% 
	 (3)
	  	FYE 2016 Relative TSR **; #	  	33-1/3%	  	Threshold	  	Company TSR is at least equal to the [***] percentile of the NBI but less than the [***] percentile of the NBI	  	 	50	% 
	  	  	  	Target	  	Company TSR is at least equal to the [***] percentile of the NBI but less or equal to the [***] percentile of the NBI	  	 	100	% 
	  	  	  	Maximum	  	Company TSR is greater than the [***] percentile of the NBI	  	 	150	% 

  
 3 

	*	The actual number of Performance Stock Units earned and vested will be based on the actual performance level achieved with respect to each performance level. If the actual performance level achieved for any Performance
Goal does not meet threshold performance (i.e., less than 50%) for the applicable Performance Goal, then no Performance Stock Units will be earned and vested for that Performance Goal pursuant to this Award. Threshold level performance may be
achieved for one Performance Goal and not another based on the Company’s actual performance during the applicable Performance Period. The actual number of Performance Stock Units earned and vested will be determined by the Committee based on
the actual performance level achieved with respect to the applicable Performance Goals during the applicable Performance Period, factoring in the weighting for each Performance Goal. The maximum number of Performance Stock Units that may become
earned and vested pursuant to this Award is capped at 150% of the Target Award. Any fractional Performance Stock Units resulting from the vesting of the Performance Stock Units in accordance with the terms herein shall be rounded down to the nearest
whole number. 

	**	Provided that threshold level performance is achieved, if actual performance is between performance levels, the number of Performance Stock Units earned and vested with respect to the Performance Goal, if any, will be
interpolated on a straight line basis for pro-rata achievement for performance at or between performance levels. 

	# 	FYE 2016 Relative TSR will be measured based on the Company’s TSR compared to the Nasdaq Biotechnology Index (“NBI”) over the Performance Period. The NBI companies will be defined as of December 31,
2016. .FYE 2016 Relative TSR will be calculated using the 20-trading day average closing price calculated using the average of the closing prices for the 20-trading day period immediately preceding the first and last day of the Performance Period
for both the Company and the NBI, assuming reinvestment of dividends on the ex-dividend date. 

  
 4 

 ANTARES PHARMA, INC. 

PERFORMANCE STOCK UNIT AWARD AGREEMENT 

(Pursuant to the Company’s 2008 Equity Compensation Plan) 

This PERFORMANCE STOCK UNIT AWARD AGREEMENT (this “Agreement”) dated as of the Date of Grant set forth in the Summary of Grant is
delivered by Antares Pharma, Inc. (the “Company”) to the individual named in the Summary of Grant (the “Grantee”). 

RECITALS 
 A. The Antares
Pharma, Inc. 2008 Equity Compensation Plan, as amended and restated (the “Plan”), provides for the grant of restricted stock units that are payable if specified performance goals are met (referred to herein as “Performance Stock
Units”), in accordance with the terms and conditions of the Plan. 
 B. The Compensation Committee of the Board of Directors of the
Company (the “Committee”) has decided to make a Performance Stock Unit Award grant as an inducement for the Grantee to promote the best interests of the Company and its stockholders. 

C. The Grantee acknowledges delivery of a copy of the Plan and the Plan prospectus together with this Summary of Grant and the Performance
Stock Unit Award Agreement. Additional copies of the Plan and the Plan prospectus are available upon request by contacting the Chief Financial Officer at (609) 359-3020. 

NOW, THEREFORE, the parties to this Agreement, intending to be legally bound hereby, agree as follows: 

1. Performance Stock Unit Grant. 
 (a)
Subject to the terms, restrictions and conditions set forth in the Summary of Grant, this Agreement and the Plan, the Company hereby grants to the Grantee the right to receive the shares of Company Stock in the amount and on the terms set forth in
the Summary of Grant upon achievement of the Performance Goals as set forth in the Summary of Grant and satisfaction of the requirements of the Vesting Schedule set forth in the Summary of Grant. No shares of Company Stock shall be issued to the
Grantee on the Date of Grant. 
 (b) The Committee shall, as soon as practicable following the last day of the Performance Period, certify
(i) the extent, if any, to which, the Performance Goals have been achieved with respect to the Performance Period and (ii) the number of shares of Company Stock, if any, earned upon attainment of the Performance Goal. Such certification
shall be final, conclusive and binding on the Grantee, and on all other persons, to the maximum extent permitted by law. In the event that the Committee makes a final determination that the Performance Goals have not been achieved, the Grantee shall
have no further rights to receive shares of Company Stock hereunder. 
 (c) The Committee may at any time prior to the final determination of
whether the Performance Goals have been attained, change the Performance Goals or change the weighting of the Performance Goals to reflect any change in the Grantee’s responsibility level or position during the course of the period beginning on
the Date of Grant and ending on the last day of the Performance Period. In addition, the Committee may, at any time prior to the final determination of whether the Performance Goals have been attained, change the Performance Goals to reflect a
change in corporate capitalization, such as a stock split or stock dividend, or a corporate transaction, such as a merger, consolidation, separation, reorganization or partial or complete liquidation, or to equitably reflect the occurrence of any
extraordinary event, any change in applicable accounting rules or principles, any change in the Company’s method of accounting, any change in applicable law, any change due to any merger, consolidation, acquisition, reorganization, stock split,
stock dividend, combination of shares or other changes in the Company’s corporate structure or shares, or any other change of a similar nature. 

  
 -1- 

 2. Stockholder Rights. Prior to the issuance, if any, of shares of Company Stock pursuant to the terms of
the Summary of Grant, this Agreement and the Plan, the Grantee shall not (a) have any of the rights or privileges of, a stockholder of the Company; (b) have the right to receive any dividends or other distributions; and (c) have any
interest in any fund or specific assets of the Company by reason of this Agreement. 
 3. Vesting. 

(a) The shares of Company Stock subject to this Agreement will become earned based on the actual level of performance achieved with respect to
the Performance Goals for the Performance Period on the terms set forth in the Summary of Grant and as determined by the Committee and provided that the Grantee satisfies the requirements of the Vesting Schedule set forth in the Summary of Grant.

 (b) If the Grantee ceases to be employed by, or provide service to, the Employer for any reason prior to the applicable Vesting Date, the
Grantee shall forfeit all rights to receive shares of Company Stock hereunder and the Grantee will not have any rights with respect to any portion of the shares of Company Stock that have not yet become vested as of the date the Grantee ceases to be
employed by, or provide service to, the Employer, irrespective of the level of achievement of the Performance Goals. 
 4. Issuance. 

(a) Shares of Company Stock equal to the number of shares of Company Stock that the Grantee earns upon achievement of the Performance Goals and
becomes vested in the right to receive in accordance with the Vesting Schedule, in each case, as set forth in the Summary of Grant shall be issued to the Grantee as set forth in the Summary of Grant and a certificate representing the Company Stock
shall be issued to the Grantee, free of the restrictions under Section 5 of this Agreement. 
 (b) The obligation of the Company to
deliver the Company Stock to the Grantee following the applicable Vesting Date shall be subject to all applicable laws, rules, and regulations and such approvals by governmental agencies as may be deemed appropriate to comply with relevant
securities laws and regulations. 
 5. Nonassignability of Company Stock. During the period prior to the certification of the Performance Goals and
prior to the Vesting Date, the right to receive shares of Company Stock may not be assigned, transferred, pledged or otherwise disposed of by the Grantee, except as permitted under the Plan or by the Committee. Any attempt to assign, transfer,
pledge or otherwise dispose of the right to receive shares of Company Stock contrary to the provisions the Summary of Grant, this Agreement and the Plan, and the levy of any execution, attachment or similar process upon the right to receive the
shares, shall be null, void and without effect. 
 6. Change of Control. Except as provided in the Summary of Grant, the provisions of the Plan
applicable to a Change of Control shall apply to the right to receive the Company Stock issuable upon attainment of the Performance Goals and satisfaction of the Vesting Schedule set forth in the Summary of Grant, and, in the event of a Change of
Control, the Committee may take such actions as it deems appropriate pursuant to the Plan. 
 7. Grant Subject to Plan Provisions. This grant is made
pursuant to the Plan, the terms of which are incorporated herein by reference, and in all respects shall be interpreted in accordance with the Plan. This grant is subject to interpretations, regulations and determinations concerning the Plan
established from time to time by the Committee in accordance with the provisions of the Plan, including, but not limited to, provisions pertaining to (a) rights and obligations with respect to withholding taxes, (b) the registration,

  
 -2- 

 
qualification or listing of the shares, (c) changes in capitalization of the Company and (d) other requirements of applicable law. The Committee shall have the authority to interpret
and construe this grant pursuant to the terms of the Plan, and its decisions shall be conclusive as to any questions arising hereunder. 
 8.
Withholding. Unless the Committee provides otherwise, the number of shares of Company Stock distributed to the Grantee with respect to the Performance Stock Units will be reduced by a number of shares sufficient to satisfy the amount of any
federal, state or local income and employment taxes associated with the distribution. Notwithstanding the foregoing, the Employer may require that the Grantee receiving any distribution or payment hereunder pay to the Employer the amount of any
federal, state or local income and employment taxes that the Employer is required to withhold with respect to such payment, or the Employer may deduct from other compensation paid by the Employer the amount of any federal, state or local income and
employment taxes due with respect to the Performance Stock Units. The Executive shall bear all expense of, and be solely responsible for, all federal, state and local income and employment taxes due with respect to any distribution or payment
received under this Agreement. In no event shall the amount of withholding exceed the minimum applicable withholding tax rate for federal (including FICA), state, local and other tax liabilities. 

9. No Employment or Other Rights. This grant shall not confer upon the Grantee any right to be retained by or in the employ or service of the Employer
and shall not interfere in any way with the right of the Employer to terminate the Grantee’s employment or service at any time. The right of the Employer to terminate at will the Grantee’s employment or service at any time for any reason
is specifically reserved. 
 10. Recoupment Policy. The Grantee agrees that the Grantee will be subject to any compensation, clawback and recoupment
policies that may be applicable to the Grantee as an employee of the Employer, as in effect from time to time and as approved by the Board of Directors or a duly authorized committee thereof, whether or not approved before or after the Date of
Grant. 
 11. Assignment by Company. The rights and protections of the Company hereunder shall extend to any successors or assigns of the Company and
to the Company’s parents, subsidiaries, and affiliates. This Agreement may be assigned by the Company without the Grantee’s consent. 
 12.
Applicable Law. The validity, construction, interpretation and effect of this instrument shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to the conflicts of laws provisions
thereof. 
 13. Notice. Any notice to the Company provided for in this instrument shall be addressed to the Chairman of the Compensation Committee at
the corporate headquarters of the Company, and any notice to the Grantee shall be addressed to such Grantee at the current address shown on the payroll of the Employer, or to such other address as the Grantee may designate to the Employer in
writing. Any notice shall be delivered by hand, sent by telecopy or enclosed in a properly sealed envelope addressed as stated above, registered and deposited, postage prepaid, in a post office regularly maintained by the United States Postal
Service. 
 14. Application of Section 409A of the Internal Revenue Code. This Agreement, including the right to receive Company Stock upon
achievement of the Performance Goals and satisfaction of the Vesting Schedule, is intended to be exempt from the requirements of section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) pursuant to the short-term deferral
exemption thereunder, and this Agreement, including the right to receive Company Stock upon the achievement of the Performance Goals and satisfaction of the Vesting Schedule, shall be interpreted on a basis consistent with such intent.
Notwithstanding any provision in this Agreement to the contrary, if the Grantee is a “specified employee” (as defined in section 409A of the Code) and it is necessary to postpone the commencement of any payments otherwise payable under
this Agreement to prevent any accelerated or additional tax under section 409A of the Code, then the Company will postpone the payment until five days after the end of 

  
 -3- 

 
the six-month period following the Grantee’s “separation from service” (as defined under section 409A of the Code). If the Grantee dies during the postponement period prior to the
payment of postponed amount, the amounts withheld on account of section 409A of the Code shall be paid to the personal representative of the Grantee’s estate within 60 days after the date of the Grantee’s death. The determination of who is
a specified employee, including the number and identity of persons considered specified employees and the identification date, shall be made by the Committee in accordance with the provisions of sections 416(i) and 409A of the Code. In no event
shall the Grantee, directly or indirectly, designate the calendar year of payment. For purposes of Section 409A of the Code, each payment under this Agreement shall be treated as a separate payment. This Agreement may be amended without the
consent of the Grantee in any respect deemed by the Committee to be necessary in order to preserve compliance with section 409A of the Code or other applicable law. 

  
 -4-EX-10.1

 Exhibit 10.1 

EMPLOYMENT AGREEMENT 

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between John Bencich (the “Executive”) and OncoGenex
Pharmaceuticals, Inc., a Washington corporation (the “Employer” or the “Company”) as of August 11, 2014 (the “Effective Date”). 
  

	 	1.	Duties and Scope of Employment. 

 For the term of this Agreement
(“Employment”), the Employer agrees to employ the Executive in the position of Vice President, Chief Financial Officer. The Executive shall report directly to the President of the Company. The Executive shall have such duties, authority
and responsibilities that are commensurate with his being a senior executive officer of the Employer. During his employment, Executive will perform his duties faithfully and to the best of his ability and will, except as provided below, devote his
full business efforts and time to the Employer. For the duration of the Executive’s Employment term, Executive agrees not to actively engage in any other employment, occupation or consulting activity for any direct or indirect remuneration
without the prior written approval of the President, such approval not to be unreasonably withheld. It is understood and agreed that Executive will not be precluded from serving on boards of directors and advisory boards, provided that such
activities do not materially adversely affect Executive’s ability to perform and discharge his duties to the Employer. The Executive’s primary work place shall be at the Employer’s corporate headquarters in Bothell, Washington,
however regular travel to the Company’s office in Vancouver, British Columbia will be required. 
  

	 	2.	Cash and Incentive Compensation. 

 (a) Salary. The Employer shall
pay the Executive as compensation for his services a base salary at a gross annual rate of not less than $300,000. Such salary shall be payable in accordance with the Employer’s standard payroll procedures. The annual compensation specified in
this Section 2(a), including any reductions that the Executive and the Employer may mutually agree to from time to time, and together with any increases in such compensation that the Employer may grant from time to time, is referred to in this
Agreement as “Base Compensation.” 
 (b) Incentive Bonuses. The Executive shall be eligible to receive a
discretionary annual fiscal year incentive bonus (“Bonus”) that the Board of Directors of the Company (the “Board”) or Compensation Committee of the Board (the “Committee”) shall determine and award in its sole
discretion. Initially, the Executive shall be eligible to receive a Bonus constituting up to 30% of the Executive’s Base Compensation. Such percentage may be modified by the Board or the Committee in its discretion from time to time. The Bonus
will be based upon the achievement of specific milestones that will be determined by the Board and/or the Committee and confirmed to the Executive no later than ninety (90) days after the start of each fiscal year. Payment for each year’s
Bonus, if awarded, shall be made to the Executive no later than the fifteenth day of the third month after the later of the end of the calendar year or the Employer’s taxable year in which the Bonus payment is no longer subject to a substantial
risk of forfeiture for purposes of Section 409A of the Internal Revenue Code, as amended (“Section 409A”). The Board or the Committee may, in its sole discretion, determine not to award a Bonus or to award a Bonus at less than
maximum eligibility. The Executive acknowledges that a Bonus is neither required nor guaranteed by this Agreement. 

 (c) Signing Bonus. The Executive shall be eligible to receive a one-time
signing bonus of $20,000, which shall be payable on the first regular payroll date following the Effective Date. 
 (d)
Equity Terms. During the Executive’s Employment, at the discretion of the Committee, the Executive shall be entitled to participate in the Company’s equity compensation plans, as in effect from time to time, and the Executive shall
be eligible to receive grants of Company equity (“Compensatory Equity”), as determined by the Committee, in its discretion from time to time. 

(e) Employee Benefits. During the Executive’s Employment, the Executive will be entitled to participate in the
employee benefit plans of general applicability to other employees of the Company, as in effect from time to time, including, without limitation, the Company’s group medical, dental, vision, disability, life insurance, director and officer
liability insurance and flexible-spending account plans. The Company reserves the right to cancel or change the benefit plans and programs it offers to its employees at any time. 

(f) “Service” Definition. For purposes of Section 3(b) of this Agreement, “Service” shall mean
service by the Executive as an employee and/or consultant of the Employer (or any subsidiary or parent or affiliated entity of the Employer). 
  

	 	3.	Paid Time Off and Indemnification. 

 (a) Paid Time Off. The
Executive will be eligible for paid time off (“PTO”) in accordance with the Employer’s PTO policy. Under the Employer’s current PTO policy, the Executive is eligible for twenty five (25) days per year of PTO. 

(b) Indemnification. The Employer shall indemnify the Executive to the maximum extent permitted by applicable law and
the Employer’s certificate of incorporation and bylaws with respect to the Executive’s Service. During the Executive’s Employment, the Employer shall maintain officers’ liability insurance for the Executive’s benefit on
terms and conditions no less favorable than the terms and conditions generally applicable to the Employer’s other senior executive officers. The Employer’s obligations under this Section 3(b) shall survive termination of the
Executive’s Service and also termination or expiration of this Agreement. 
  

	 	4.	Business Expenses. 

 During his Employment, the Executive shall be authorized to incur
necessary and reasonable travel, entertainment and other business expenses in connection with his duties hereunder. The Employer shall promptly reimburse the Executive for such expenses upon presentation of appropriate supporting documentation, all
in accordance with the Employer’s generally applicable policies. 

  
 -2- 

	 	5.	Term of Employment. 

 (a) Employment-at-Will. The Employer and the
Executive hereby acknowledge that the Executive’s Employment is at-will. The Employer may terminate the Executive’s Employment with or without Cause, by giving the Executive either, in the Employer’s sole discretion, (a) thirty
(30) days advance notice in writing, or (b) a cash payment equivalent to 30 calendar days of the then-effective Base Compensation in lieu of providing such notice. The Executive may terminate his Employment by giving the Employer thirty
(30) days advance notice in writing. The Executive’s Employment shall terminate automatically in the event of his death. 

(b) Rights Upon Termination. Upon the termination of the Executive’s Employment for any reason (including death or
Disability (as defined below)), the Executive shall be entitled to the compensation, benefits and reimbursements described in this Agreement through the effective date of the termination (the “Termination Date”), and the Employer shall
make the following payments to the Executive (or his beneficiary) within 10 business days following the Termination Date: (i) all unpaid salary and unpaid PTO accrued through the Termination Date, (ii) any accrued, unpaid bonuses (provided
that any such bonus has been awarded by the Board or the Committee, in accordance with the terms of any applicable plan, has been earned by the Executive and is not subject to any vesting or other similar requirement) for any fiscal year of the
Employer ended prior to the Termination Date and (iii) any unreimbursed business expenses provided that Executive has submitted appropriate documentary substantiation as required by Company policy. The Executive may also be eligible for other
post-Employment payments and benefits as provided in this Agreement or pursuant to other agreements (other than the Prior Agreements) or plans with the Employer. Upon the Termination Date, the Executive shall have no further rights to receive
compensation or benefits from the Employer except as set forth in Section 6 and pursuant to the terms of any benefit plans (including without limitation any equity compensation plans) of the Company in which the Executive is a participant. 

 

	 	6.	Termination Benefits. 

 (a) Severance Pay. If there is an
Involuntary Termination (as defined below) of the Executive’s Employment, then, subject to the Executive’s execution, delivery and non-revocation of a Release (defined below) within the time period described below, following the
Executive’s “separation from service” within the meaning of Section 409A, the Employer shall pay the Executive a single lump sum of cash in an amount equal to the sum of nine (9) months (the “Severance Period”) of
the Executive’s then annual Base Compensation (not giving effect to any reduction in Base Compensation made in connection with such Involuntary Termination or giving rise to Good Reason). The cash lump sum amount payable under this
Section 6(a) shall be made to the Executive on the first payroll date in the month following the month containing the Release Deadline. The Executive shall also receive the benefits provided in Sections 6(b) and 6(c), and all such payments
and benefits shall not be subject to mitigation or offset (except as specified in Section 6(b)). In order to be entitled to receive the severance described in this Section 6(a) (including the benefits provided in Sections 6(b), 6(c)
and, if applicable, 6(d)), the Executive must execute, deliver and not revoke the Release within forty-five (45) calendar days following the Executive’s separation from 

  
 -3- 

 
service (the date that is forty-five (45) calendar days following the Executive’s separation from service is the “Release Deadline”). The Employer shall furnish the Release to
the Executive on the date of his Involuntary Termination. The “Release” shall be a general release of all litigation and other claims against the Employer and all affiliates by the Executive and on Executive’s behalf in a form
satisfactory to the Employer. 
 (b) Health Insurance. If the Executive is entitled to receive the severance payment
in Section 6(a), and if the Executive elects to continue his (and his dependents’) health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), then the Employer shall pay in a lump sum
payment the number of months of the Executive’s monthly premium under COBRA that is equal to the number of months in the Severance Period. The cash lump sum amount payable under this Section 6(b) shall be made to the Executive on the first
payroll date in the month following the month containing the Release Deadline. 
 (c) Equity Vesting. Notwithstanding
the terms of any equity compensation plan of the Company or any agreement in connection with a grant of Compensatory Equity, if the Executive is entitled to receive the payments in Section 6(a), then the time-based vesting restrictions (if any)
shall immediately lapse on an additional number of shares of Company common stock under all of the Executive’s outstanding Compensatory Equity that is equal to the number of shares that would have time-vested if the Executive had continued in
employment for the number of additional months following the Termination Date that is equal to the number of months in the Severance Period. The Executive shall be entitled to exercise any of his Compensatory Equity to the extent vested pursuant to
this Section 6(c) or otherwise for such period as set forth in the terms of that Compensatory Equity. 
 (d) Effect
of Change in Control. If the Company is subject to a Change in Control (as defined below) and there is an Involuntary Termination of the Executive’s Employment within the period beginning three (3) months before and ending twelve
(12) months after a Change in Control (or more than three (3) months prior to a Change in Control but in connection with a Change in Control), then following the Executive’s separation from service, the Executive will be entitled to
all benefits described in Sections 6(a), 6(b) and 6(c) of this Agreement subject to the same terms and conditions and payment dates described above, except that (x) the cash payment amount under Section 6(a) shall be an amount equal
to the sum of twelve (12) months of the Executive’s then annual Base Compensation (not giving effect to any reduction in Base Compensation made in connection with such Involuntary Termination or giving rise to Good Reason), plus an amount
equal to the sum of twelve (12) months of the Executive’s average monthly Bonus earnings, where such average is calculated over the twenty-four (24) month period immediately preceding the Executive’s separation from service and
based on the Executive’s Bonus paid in such 24 month period, or if Executive was employed less than twenty-four (24) months 30% of Executive’s then annual Base Compensation, (y) the Employer’s payment of monthly COBRA
premiums under Section 6(b) shall be for up to twelve (12) months and (z) notwithstanding the terms of any equity compensation plan of the Company or any agreement in connection with a grant of Compensatory Equity, all vesting
restrictions (if any) shall immediately lapse on all of the Executive’s Compensatory Equity effective as of the Executive’s separation from service. For purposes of the preceding sentence, an Involuntary Termination shall be deemed to be
in 

  
 -4- 

 
connection with a Change in Control if such termination (i) is required by the merger agreement, purchase agreement or other instrument relating to such Change in Control or (ii) is
made at the express request of the other party (or parties) to the transaction constituting such Change in Control. 
 (e)
Parachute Payments. In the event that the payments and benefits provided for in this Agreement and the payments and/or benefits provided to, or for the benefit of, the Executive under any other Employer plan or agreement (such payments or
benefits are hereinafter collectively referred to as the “Benefits”) (i) constitute “parachute payments” within the meaning of Section 280G of the Internal Revenue Code and (ii) but for this Section 6(e),
would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code (the “Excise Tax”), then the Benefits shall either be: 

(i) delivered in full, or 

(ii) delivered as to such lesser extent which would result in no portion of such Benefits being subject to the Excise Tax (such
reduced amount is hereinafter referred to as the “Limited Amount”), 
 whichever of the foregoing amounts, taking into account the applicable
federal, state and local income taxes and the Excise Tax, results in the receipt by the Executive on an after-tax basis, of the greatest amount of Benefits, notwithstanding that all or some portion of such Benefits may be subject to the Excise Tax.
If applicable, in order to effectuate the Limited Amount, the Employer shall first reduce those Benefits which are payable in cash and then reduce non-cash payments, in each case in reverse order beginning with Benefits which are to be paid the
farthest in time from the date of determination that the Benefits will be limited by (e)(ii) above. Any calculations and determinations required under this Section 6(e) shall be made in writing by the Company’s independent auditor (the
“Accountant”) whose determination shall be conclusive and binding. The Executive and the Company shall furnish the Accountant such documentation as the Accountant may reasonably request in order to make a determination. The Employer shall
pay for all costs that the Accountant may reasonably incur in connection with performing any calculations contemplated by this Section 6(e). 

(f) “Change in Control” Definition. For purposes of this Agreement, “Change in Control” shall mean
the occurrence of any of the following events: 
 (i) the consummation of a merger or consolidation of the Company with or
into another entity or any other corporate reorganization, if the Company’s stockholders immediately prior to such merger, consolidation or reorganization cease to directly or indirectly own immediately after such merger, consolidation or
reorganization at least a majority of the combined voting power of the continuing or surviving entity’s securities (or, if the continuing or surviving entity is a wholly owned subsidiary of another corporation immediately following such merger
or consolidation, the ultimate parent corporation of such surviving or resulting corporation) outstanding immediately after such merger, consolidation or other reorganization; 

  
 -5- 

 (ii) the consummation of the sale, transfer or other disposition of all or
substantially all of the Company’s assets (other than (1) to a corporation or other entity of which at least a majority of its combined voting power is owned directly or indirectly by the Company, (2) to a corporation or other entity
owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company or (3) to a continuing or surviving entity described in subsection (i) in
connection with a merger, consolidation or corporate reorganization which does not result in a Change in Control under subsection (i)); 

(iii) a change in the composition of the Board, as a result of which fewer than one-half of the incumbent directors are
directors who either (1) had been directors of the Company on the date twenty-four (24) months prior to the date of the event that may constitute a Change in Control (the “original directors”) or (2) were elected, or
nominated for election, to the Board with the affirmative votes of at least a majority of the aggregate of the original directors who were still in office at the time of the election or nomination and the directors whose election or nomination was
previously so approved; 
 (iv) the consummation of any transaction as a result of which any person becomes the
“beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), directly or indirectly, of securities of the Company representing at least thirty-five percent
(35%) of the total voting power represented by the Company’s then outstanding voting securities. For purposes of this subsection, the term “person” shall have the same meaning as when used in sections 13(d) and 14(d) of the
Exchange Act but shall exclude: 
 (1) a trustee or other fiduciary holding securities under an employee benefit plan of the
Company or an affiliate of the Company; 
 (2) a corporation or other entity owned directly or indirectly by the
stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company; 

(3) the Company; and 

(4) a corporation or other entity of which at least a majority of its combined voting power is owned directly or indirectly by
the Company; or 
 (v) a complete winding up, liquidation or dissolution of the Company. 

For purposes of this Section 6(f), a transaction shall not constitute a Change in Control if its sole purpose is to change the state of
the Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transactions. 

(g) “Cause” Definition. For all purposes under this Agreement, “Cause” shall mean any of the
following committed by the Executive: 
 (i) Willful failure to follow the reasonable and lawful directions of President of
the Company; 

  
 -6- 

 (ii) Conviction of a felony (or a plea of guilty or nolo contendere by the
Executive to a felony) that materially harms the Company; 
 (iii) Acts of fraud, dishonesty or misappropriation committed by
the Executive; 
 (iv) Willful misconduct by the Executive in the performance of the Executive’s material duties
required by this Agreement; or 
 (v) A material breach of this Agreement. 

The foregoing is an exclusive list of the acts or omissions that shall be considered “Cause” for the termination of the
Executive’s Employment by the Employer. With respect to the acts or omissions set forth in clauses (i), (iii), (iv) and (v) above, (x) the President shall provide the Executive with one (1) month advance written notice
detailing the basis for the termination of Employment for Cause, (y) during the one-month period after the Executive has received such notice, the Executive shall have an opportunity to cure such alleged Cause events before any termination for
Cause is finalized and (z) the Executive shall continue to receive the compensation and benefits provided by this Agreement during the one-month cure period. In addition, no act or failure to act of Executive shall be willful or intentional if
performed in good faith with the reasonable belief that the action or inaction was in the best interest of the Employer. 

(h) “Involuntary Termination” Definition. For all purposes under this Agreement, “Involuntary
Termination” shall mean any of the following: (i) termination of the Executive’s Employment by the Employer without Cause; (ii) the Executive’s resignation of Employment for Good Reason; or (iii) termination of the
Executive’s Employment by the Employer for Disability. 
 (i) “Good Reason” Definition. For all
purposes under this Agreement, “Good Reason” shall mean any of the following that occurs without the Executive’s prior written consent: (i) the relocation of the Executive’s primary work location by more than forty
(40) miles from the Employer’s current location in Bothell, Washington; (ii) a material reduction of the Executive’s Base Compensation (excluding any material reduction that the Executive and the Employer may mutually agree to
from time to time) or Executive’s employee benefits; (iii) any material reduction or diminution of the Executive’s duties, authority or responsibilities; (iv) the Employer’s material breach of this Agreement; or (v) the
failure of any successor of the Company to expressly in writing assume the Company’s obligations under this Agreement, in each case, provided that the Executive shall have provided the Employer with thirty (30) days advance written notice
and an opportunity to cure such breach during such 30-day period. 
 (j) “Disability” Definition. For all
purposes under this Agreement, “Disability” shall mean the Executive’s incapacity due to physical or mental illness to perform his full-time duties with the Employer for a continuous period of three (3) months or an aggregate of
six (6) months in any eighteen (18) month period. 

  
 -7- 

	 	7.	Non-Solicitation, Non-Compete and Non-Disparagement. 

 (a)
Non-Solicitation. During the period commencing on the date of this Agreement and continuing until the first anniversary of the Termination Date, the Executive shall not directly or indirectly, personally or through others, solicit, recruit,
or attempt to solicit or recruit any employee, agent, licensor, content provider, supplier, distributor, customer or partner of the Company to curtail, cancel or terminate such employment, agency or business relationship that it has with the Company
or its affiliates. 
 (b) Non-Compete. During the period commencing on the date of this Agreement and continuing until
the first anniversary of the Termination Date, the Executive shall not directly or indirectly, personally or through others, own, manage, operate, control, participate in, perform services for, make any investment in, assist, or otherwise carry on,
the Company business (such business, including the business of any subsidiary or parent or affiliated entity of the Company, is referred to herein as the “Company Business”) or any business that directly competes with the Company Business
(other than in the course of performing duties to the Company or any of its affiliates as an employee or other service provider). Notwithstanding the foregoing, nothing contained in this Section 7(b) shall limit or otherwise affect the ability
of Executive to own not more than 1.0% of the outstanding capital stock of any entity that is engaged in a business competitive with the Company Business, provided that such investment is a passive investment and the Executive is not directly or
indirectly involved in the management or operation of such business or otherwise providing consulting services to such business. For purposes of this Agreement, Company Business shall include, but shall not be limited to the research and development
of the Technology, as defined herein, and such other business plans as approved by the Board from time to time and which are in effect on the Termination Date. As used herein, “Technology” means all ideas, concepts, business and trade
names, trademarks, know-how, trade secrets, inventions, improvements, devices, methods, processes and discoveries, whether patentable or not, and whether or not reduced to writing or other tangible form or to actual or constructive practice which
either: (i) are part of the technology licensed to OncoGenex Technologies Inc. under the UBC Licenses, as defined herein, or (ii) are otherwise developed or acquired on behalf of or by the Company or any affilate of the Company, including
but not limited to the technology licensed to the Company or any affiliate of the Company by clients for work to be performed for such clients pursuant to research contracts. As used herein, “UBC Licenses” means the licenses entered into
by the University of British Columbia and OncoGenex Technologies Inc. effective November 1, 2001, September 1, 2002 and April 5, 2005 which define the terms under which OncoGenex Technologies Inc. has acquired an exclusive
license to certain technology. It is understood that OncoGenex Technologies Inc. has granted the Company a limited right to use certain technology licensed under the UBC Licenses solely for the Company to perform work for OncoGenex Technologies Inc.

 (c) Confidential Information. Except as required in the good faith opinion of the Executive in connection with the
performance of the Executive’s duties hereunder or as specifically set forth in this Section 7(c), the Executive shall, in perpetuity, maintain in 

  
 -8- 

 
confidence and shall not directly, indirectly or otherwise, use, disseminate, disclose or publish, or use for his benefit or the benefit of any person, firm, corporation or other entity any
confidential or proprietary information or trade secrets of or relating to the Company or any of its affiliates, including, without limitation, information with respect to the Company’s operations, processes, products, inventions, business
practices, finances, principals, vendors, suppliers, customers, potential customers, marketing methods, costs, prices, contractual relationships, regulatory status, business plans, designs, marketing or other business strategies, compensation paid
to employees or other terms of employment, or deliver to any person, firm, corporation or other entity any document, record, notebook, computer program or similar repository of or containing any such confidential or proprietary information or trade
secrets. The Company and the Executive stipulate and agree that as between them the foregoing matters are important, material and confidential proprietary information and trade secrets and affect the successful conduct of the businesses of the
Company (and any successor or assignee of the Company). Upon termination of the Executive’s employment with the Company for any reason, the Executive shall promptly deliver to the Company all correspondence, drawings, manuals, letters, notes,
notebooks, reports, programs, plans, proposals, financial documents, or any other documents concerning the Company’s customers, business plans, designs, marketing or other business strategies, products or processes, provided that the Executive
may retain his rolodex, address book and similar information, whether or not the Company specifically requests it. 
 (d)
Non-Disparagement. The Executive and the Company mutually agree not to disparage or defame, in writing or orally, the other party, and as applicable, its or his services, products, subsidiaries and affiliates, and/or their respective
directors, officers, employees, agents, family members, successors and assigns. This non-disparagement provision shall not apply to statements made by non-management employees of the Company, so long as such statements did not originate from and
were not induced or encouraged (directly or indirectly) by an officer, director or management employee of the Company. Notwithstanding the foregoing, nothing in this Section 7(d) shall limit the ability of the Company or the Executive, as
applicable, to provide truthful testimony as required by law or any judicial or administrative process. 
 (e)
Remedies. Without limiting the right of the Employer to pursue all other legal and equitable rights available to the Employer for violation of the provisions of Section 7 of this Agreement by Executive, it is agreed that (a) other
remedies cannot fully compensate the Employer for such a violation, (b) such a violation will cause the Employer irreparable harm which may not be adequately compensated by money damages and (c) the Employer shall each be entitled to
temporary, preliminary and permanent injunctive or other equitable relief, without proving actual damages or posting a bond therefore, to prevent a violation, continuing violation or threatened violation of the provisions of Section 7 of this
Agreement. 
  

	 	8.	Inventions and Patents. 

 (a) For purposes of this Agreement,
“Inventions” includes, without limitation, information, inventions, contributions, improvements, ideas, or discoveries, whether protectable or not, and whether or not conceived or made during work hours. Executive agrees

  
 -9- 

 
that all Inventions conceived or made by Executive during the period of employment with Employer belong to Employer, provided they grow out of Executive’s work with Employer or are related
in some manner to the Company Business, including, without limitation, research and product development, and projected business of Employer or its affiliated companies. Accordingly, Executive will: 

(i) Make adequate written records of such Inventions, which records will be Employer’s property; 

(ii) Assign (and hereby does irrevocably assign and transfer) to Employer or its designee, at Employer’s request, any
rights, title and interest Executive may have to such Inventions for the U.S. and all foreign countries; 
 (iii) Waive and
agree not to assert any moral rights Executive may have or acquire in any Inventions and agree to provide written waivers from time to time as requested by Employer; and 

(iv) Assist Employer (at Employer’s expense) in obtaining and maintaining patents or copyright registrations with respect
to such Inventions. 
 (b) Executive understands and agrees that Employer or its designee will determine, in its sole and
absolute discretion, whether an application for patent will be filed on any Invention that is the exclusive property of Employer, as set forth above, and whether such an application will be abandoned prior to issuance of a patent. Employer will pay
to Executive, either during or after the term of this Agreement, the following amounts if Executive is sole inventor, or Executive’s proportionate share if Executive is joint inventor: $750 upon filing of the initial application for patent on
such Invention; and $1,500 upon issuance of a patent resulting from such initial patent application, provided Executive is named as an inventor in the patent. 

(c) Executive further agrees that Executive will promptly disclose in writing to Employer during the term of Executive’s
employment and for one (1) year thereafter, all Inventions whether developed during the time of such employment or thereafter (whether or not Employer has rights in such Inventions) so that Executive’s rights and Employer’s rights in
such Inventions can be determined. Except as set forth on the initialed Exhibit A (List of Inventions) to this Agreement, if any, Executive represents and warrants that Executive has no Inventions, software, writings or other works of authorship
useful to Employer in the normal course of the Company Business, which were conceived, made or written prior to the date of this Agreement and which are excluded from the operation of this Agreement. 

(d) NOTICE: In accordance with Washington law, this Section 8 does not apply to Inventions for which no
equipment, supplies, facility, or trade secret information of Employer was used and which was developed entirely on Executive’s own time, unless: (a) the Invention relates (i) directly to the business of Employer or (ii) to
Employer’s actual or demonstrably anticipated research or development, or (b) the Invention results from any work performed by Executive for Employer. 

  
 -10- 

	 	9.	Successors. 

 (a) Employer’s Successors. This Agreement shall
be binding upon any successor (whether direct or indirect and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Employer’s business and/or assets. For all purposes under this
Agreement, the term “Employer” shall include any successor to the Employer’s business and/or assets which becomes bound by this Agreement. 

(b) Employee’s Successors. This Agreement and all rights of the Executive hereunder shall inure to the benefit of,
and be enforceable by, the Executive’s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. 
  

	 	10.	Section 409A of the Internal Revenue Code. 

 In the event that the Employer
determines that any of the benefits payable under this Agreement would violate Section 409A, then the Employer and the Executive shall, in good faith, agree to implement adjustments needed to comply with Section 409A. Additionally,
notwithstanding anything contained in this Agreement to the contrary, if Executive is deemed by the Employer at the time of Executive’s “separation from service” to be a “specified employee,” each within the meaning of
Section 409A, any compensation or benefits to which Executive becomes entitled under this Agreement (or any agreement or plan referenced in this Agreement) in connection with such separation that are subject to Section 409A shall not be
made or commence until the date which is six (6) months after Executive’s “separation from service” (or, if earlier, Executive’s death). Such deferral shall only be effected to the extent required to avoid adverse tax
treatment to Executive, including (without limitation) the additional twenty percent (20%) tax for which Executive would otherwise be liable under Section 409A(a)(1)(B) in the absence of such deferral. Upon the expiration of the applicable
deferral period, any compensation or benefits which would have otherwise been paid during that period (whether in a single lump sum or in installments) in the absence of this Section 10 shall be paid to Executive or Executive’s beneficiary
in one lump sum. 
  

	 	11.	Repayment Provisions. 

 If the Company is required to prepare an accounting restatement
due to its material noncompliance, as a result of the Executive’s misconduct, with any financial reporting requirement under United States securities laws, then, and only if Section 304 of the Sarbanes-Oxley Act of 2002, or a successor
provision, is then in effect, the Company may require the Executive to reimburse the Employer for (i) any bonus or other incentive-based or equity-based compensation received by the Executive from the Employer during the 12-month period
following the first public issuance or filing with the Securities Exchange Commission (whichever first occurs) of the financial documents embodying such financial reporting requirement and (ii) any profits realized from the sale of securities
of Company during such 12-month period. 
  

	 	12.	Miscellaneous Provisions. 

 (a) Notice. Notices and all other
communications contemplated by this Agreement shall be in writing and shall be deemed to have been duly given when personally 

  
 -11- 

 
delivered or when mailed by overnight courier, U.S. registered or certified mail, return receipt requested and postage prepaid. In the case of the Executive, mailed notices shall be addressed to
him at the home address that he most recently communicated to the Employer in writing. In the case of the Employer, mailed notices shall be addressed to: 
  

					
	Attention:	 	President
	c/o:	 	1522 217th Place SE, Suite 100
		 	Bothell, Washington 98021
		 	Telephone:	 	425-686-1500
		 	Facsimile:	 	425-686-1600

 (b) Modifications and Waivers. No provision of this Agreement shall be modified, waived
or discharged unless the modification, waiver or discharge is agreed to in writing and signed by the Executive and by an authorized officer of the Employer (other than the Executive). No waiver by either party of any breach of, or of compliance
with, any condition or provision of this Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time. 

(c) Whole Agreement. Except for those agreements or plans referenced herein (including without limitation any employee
benefit plans of the Company in which the Executive is a participant in as of the Effective Date), this Agreement contains the entire understanding of the parties with respect to the subject matter hereof and supersedes any other agreements,
representations or understandings (whether oral or written and whether express or implied) with respect to the subject matter hereof. In the event of any conflict in terms between this Agreement and any other agreement executed by and between the
Executive and the Employer, the terms of this Agreement shall prevail and govern. 
 (d) Withholding Taxes. All
payments made under this Agreement shall be subject to reduction to reflect taxes or other charges required to be withheld by law. 

(e) Choice of Law. The validity, interpretation, construction and performance of this Agreement shall be governed by the
laws of the State of Washington (except their provisions governing the choice of law). 
 (f) Severability;
Blue-Penciling. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity or enforceability of any other provision hereof, which shall remain in full force and effect. Furthermore, it is
the intent, agreement and understanding of each party hereto that if, in any action before any court or agency legally empowered to enforce this Agreement, any term, restriction, covenant or promise in this Agreement is found to be unreasonable and
for that or any other reason unenforceable, then such term, restriction, covenant or promise shall be deemed modified to the minimum extent necessary to make it enforceable by such court or agency; provided further that any such court or agency
shall have the power to modify such provision, to the extent necessary to make it enforceable (for the maximum duration and geographic scope permissible), and such provision as so modified shall be enforced. 

  
 -12- 

 (g) Assignment. The Employer may assign its rights under this Agreement to
any entity that expressly in writing assumes the Employer’s obligations hereunder in connection with any sale or transfer of all or substantially all of the Company’s assets to such entity. 

(h) Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. 
  

									
	ONCOGENEX PHARMACEUTICALS, INC.	 		 	JOHN BENCICH
					
	By:	 	 /s/ Scott Cormack
	 		 	Signed:	 	 /s/ John Bencich

					
	Name:	 	Scott Cormack	 		 		 	
	Its:	 	President and Chief Executive Officer	 		 		 	

  
 -13-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]